Glucagon/GLP-1 receptor dual agonist demonstrates efficacy for obesity and MASLD

Biased Dual-Agonists of GLP-1 and Glucagon Receptors Developed Through Conserved Aspartate Mutation

This article describes a scientific discovery where researchers engineered biased dual-agonists of the glucagon-like peptide 1 receptor (GLP

Two Observational Studies Link GLP-1 Receptor Agonists to Reduced Breast Cancer Risk in Women with Obesity

Two observational studies found that GLP-1 receptor agonists (like Ozempic, Wegovy) are associated with reduced breast cancer incidence in w

Triple hormone drug retatrutide shows promise for diabetes and weight loss in Lancet trial

A new triple hormone drug called retatrutide, which mimics GLP-1, GIP, and glucagon, has shown promising results in a Lancet-published trial

Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption

This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica

GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)

Obesity care's next generation will combine GLP-1 drugs with personalized therapies and advanced procedures

The article discusses how GLP-1 drugs like Ozempic, Wegovy, and Zepbound have transformed obesity treatment, but experts predict the future